Methotrexate loaded solid lipid nanoparticles (SLN) for effective treatment of carcinoma.
Solid Lipid Nanoparticles (SLN) containing Methotrexate (MTX), an anticancer drug for intravenous administration was formulated and characterized. The SLN dispersions with MTX, stearic acid, and soya lecithin in the ratio of 1:4:1, 1:4:1.5, and 1:4:2, sodium taurodeoxycholate and distilled water were prepared by micro emulsification solidification method. The results show that the prepared MTX-SLN particles (with MTX-Stearic acid-Soya lecithin--1:4:2) have an average size of 270 nm with 51.3% drug entrapment. The in-vitro release was attained up to 15th h. The pharmacokinetic study reveals that the half-life and MRT of SLNs were higher than MTX solution. The life span of EAC (Ehrlich Ascite Carcinoma) bearing mice was increased when treated with MTX-SLNs (Methotrexate nanoparticles). These results clearly indicate that SLNs are a promising sustained release drug targeting system for lipophilic antitumour drugs.
Ruckmani
K
K
Department of Pharmaceutical Engineering and Technology, School of Engineering and Technology, Bharathidasan University, Tiruchirappalli 620024, India.
Sivakumar
M
M
Ganeshkumar
P A
PA
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000737:chemistry; D004337:Drug Carriers / Q000737:chemistry*; D005260:Female; D008055:Lipids / Q000737:chemistry*; D008297:Male; D008657:Metabolic Clearance Rate; D008727:Methotrexate / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D051379:Mice; D049329:Nanostructures / Q000737:chemistry* / Q000648:ultrastructure; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D010316:Particle Size; D015996:Survival Rate; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D004337:Drug Carriers; D008055:Lipids; D008727:Methotrexate